PRODUCT CENTER
特色產(chǎn)品當(dāng)前位置:首頁 > 特色產(chǎn)品
mCherry是一種紅色熒光蛋白,它是從珊瑚Discosoma sp.中發(fā)現(xiàn)的熒光蛋白DsRed改良而來的。mCherry具有以下幾個(gè)特點(diǎn):
1. 亮度高:mCherry是一種非常亮的熒光蛋白,這使得它在顯微鏡下容易觀察。
2. 成熟速度快:與DsRed相比,mCherry的成熟速度更快,這有助于減少在細(xì)胞內(nèi)形成聚集體的可能性。
3. 光穩(wěn)定性好:mCherry具有較好的光穩(wěn)定性,適合長時(shí)間觀察。
4. pH穩(wěn)定性:mCherry對pH的敏感性較低,這使得它在不同的細(xì)胞環(huán)境中都能保持熒光特性。
5. 應(yīng)用廣泛:mCherry廣泛應(yīng)用于細(xì)胞生物學(xué)研究,包括蛋白質(zhì)定位、細(xì)胞標(biāo)記、活細(xì)胞成像等。
6. 光譜特性:mCherry的吸收峰大約在587-590納米,發(fā)射峰在610-615納米,這使得它適合與其他熒光蛋白(如GFP或YFP)進(jìn)行多色標(biāo)記和成像。
7. 遺傳編碼:mCherry可以通過基因工程手段融合到目標(biāo)蛋白上,用于研究蛋白質(zhì)的表達(dá)、定位和相互作用。
8. 轉(zhuǎn)基因模型:mCherry也常被用于構(gòu)建轉(zhuǎn)基因動(dòng)物模型,以研究特定基因的功能和調(diào)控。
mCherry的這些特性使其成為生物醫(yī)學(xué)研究中一個(gè)非常有用的工具。通過將mCherry與其他蛋白質(zhì)或肽段融合,研究人員可以觀察和分析目標(biāo)蛋白在細(xì)胞內(nèi)的行為和功能。
Anti-mCherry,抗mCherry(Cherry熒光蛋白)山羊多克隆抗體,貨號AB0040-200/AB0040-500,應(yīng)用包括WB, IHC (F), IHC (P), IF, IEM。
Anti-mCherry,AB0040-200/AB0040-500應(yīng)用示例:

免疫熒光--利用mccherry - rab11a轉(zhuǎn)導(dǎo)的MCR細(xì)胞使用抗mCherry抗體處理;
用甲醇和抗rab11a抗體按1/250的比例固定細(xì)胞。

1/ 1000稀釋的抗mCherry抗體;轉(zhuǎn)染myc-mCherry的293細(xì)胞。

免疫熒光檢測:在果蠅(Drosophila)幼蟲的神經(jīng)肌肉接頭(NMJ)處,神經(jīng)元表達(dá)mCherry熒光蛋白的轉(zhuǎn)基因果蠅模型。使用1/ 1000稀釋的抗mCherry 抗體(一抗)和1/500稀釋的抗山羊IgY抗體偶聯(lián)DyLight?488(二抗)。

免疫金標(biāo)記RPE,體內(nèi)注射mCherry表達(dá)載體。

用mcherry Rab1a腺病毒轉(zhuǎn)導(dǎo)293 HEK細(xì)胞,使用抗mCherry抗體進(jìn)行染色。

mcherry - EEA1轉(zhuǎn)染的COS-7細(xì)胞使用抗mcherry抗體(1/100稀釋)。

免疫熒光--用mCherry-Rab11a轉(zhuǎn)導(dǎo)的hCEC細(xì)胞應(yīng)用抗mcherry抗體;用甲醇和抗ra11a抗體按1/250的稀釋比例固定細(xì)胞。
Anti-mCherry,抗mCherry (紅色熒光蛋白)山羊多克隆抗體的部分引用文獻(xiàn):
| Dutta SB, Linneweber GA, Andriatsilavo M, et al. Curr Bio 2023 Jan | PMID: 36640763 |
| Balmer TS, Trussell LO. Bio Protoc 2022 May | PMID: 35813023 |
| Viheriala T, MSc Thesis, University of Tampere, Finland 2014 | |
| Merienne N, Delzor A, Viret A, et al. Gene Thep 2015 Oct | PMID: 26109254 |
| Sargiannidou I, Kim GH, Kyriakoudi S, et al. Neurogenetics 2015 Jul | PMID: 25771809 |
| Vyas P, Wu JS, Zimmerman A, et al. J. Assoc. Res. Otolaryngol 2016 Sep | PMID: 27696081 |
| Falkner S, Grade S, Dimou L, et al. Nature 2016 Oct | PMID: 27783592 |
| Espinosa-Medina I, Saha O, Boismoreau F, et al. Science 2016 Nov. Supplemental Information, | PMID: 27856909 |
| Krishnamurthy VV, Khamo JS, Mei W, et al. Development 2016 Nov | PMID: 27697903 |
| Abraira VE, Kuehn ED, Chirila AM, et al. Cell 2017 Jan | PMID: 28041852 |
| Agarwal A, Wu PH, Hughes EG, et al. Neuron 2017 Feb | PMID: 28132831 |
| Shevelkin AV, Terrillion CE, Abazyan BN, et al. Neurobiol Dis 2017 Apr | PMID: 28392471 |
| Castellano JM, Mosher KI, Abbey RJ, et al. Nature 2017 Apr | PMID: 28424512 |
| Saito M, Otsu W, Hsu KS, et al. EMBO Rep 2017 Jun | PMID: 28607034 |
| Kodani S, Soya S, Sakurai T. J Neurosc 2017 Jun | PMID: 28642284 |
| Rocca CJ, Goodman SM, Dulin JN, et al. Sci Transl Med 2017 Oct | PMID: 29070698 |
| Oliveira CR, Lemaitre R, Tazaki A, et al. Dev Biol 2017 Oct | PMID: 29198566 |
| Lin B, Coleman JH, Peterson JN, et al. Cell Stem Cell 2017 Nov | PMID: 29174332 |
| Miesfeld JB, Glaser T, Brown NL. Gene Expr Patterns 2017 Dec | PMID: 29225067 |
| Liu XS, Wu H, Krzisch M, et al. Cell 2018 Feb | PMID: 29456084 |
| Miesfeld JB, Moon MS, Riesenberg AN, et al. Sci Rep 2018 Jul | PMID: 29977079 |
| Cardoso T, Adler A, Mattsson B, et al. J Comp Neurol 2018 Jul | PMID: 30007046 |
| Movahedi K, Wiegmann R, De Vlaminck K, et al. Biotechnol Bioeng 2018 Jul | PMID: 29573361 |
| Al-Osta I, Mucha M, Pereda D, et al. Front Cell Neurosci 2018 Jul | PMID: 30072872 |
| D'Agostino G, Lyons D, Cristiano C, et al. Cell Metab 2018 Aug | PMID: 30146485 |
| Pedone E, Rocca DL, Postiglione L, et al. bioRxiv 404699; Sept 2018 | |
| Deshpande D, PhD Thesis, Ruperto-Carola University of Heidelberg, Germany 2018 | |
| Gao R, PhD Thesis, Northwestern University, USA 2018 | |
| Whissell PD, Bang JY, Khan I, et al. eNeuro 2019 Jan-Feb. | PMID: 30834305 |
| Guerrero-Juarez CF, Dedhia PH, Jin S, et al. Nat Commun 2019 Feb | PMID: 30737373 |
| MacDonald AJ, Holmes FE, Beall C, et al. bioRxiv 2019 | |
| Kumamaru H, Lu P, Rosenzweig ES, et al. Cell Rep 2019 Feb | PMID: 30811984 |
| Otsu W, Hsu YC, Chuang JZ, et al. J Neurosci 2019 Feb | PMID: 30819798 |
| Zhou X, Oishi Y, Cherasse Y, et al. Neurochem Int 2019 Mar | PMID: 30690114 |
| Balmer TS, Trussell LO. Elife 2019 Apr. | PMID: 30994458 |
| Krause T, Spindler L, Poeck B, et al. Curr Biol 2019 May | PMID: 31104933 |
| Cherqui S - US Patent App. 16/082,487, 2019 | |
| Pepe-Mooney BJ, Dill MT, Alemany A, et al. Cell Stem Cell 2019 May | PMID: 31080134 |
| Binder S, Molle M, Lippert M. J Neurosci 2019 Jul | PMID: 31285301 |
| Rusu P, Shao C, Neuerburg A, et al. Cell Stem Cell 2019 Jul | PMID: 31303549 |
| Hsu KS, Otsu W, Li Y, et al. Sci Rep 2019 Aug | PMID: 31439888 |
| Zheng Y, Liu P, Bai L, et al. Neuron 2019 Aug | PMID: 31248728 |
| Adler AF, Cardoso T, Nolbrant S, et al. Cell Rep 2019 Sep | PMID: 31553914 |
| Ceto S, Sekiguchi KJ, Takashima, Y, et al. bioRxiv Oct 2019 | |
| Pedone E, Postiglione L, Aulicino F, et al. Nat Commun 2019 Oct | PMID: 31578371 |
| Paixao S, Loschek L, Gaitanos L, et al. Neuron 2019 Oct | PMID: 31586516 |
| Riera TI, PhD Thesis, University of Munich, Germany 2019 | |
| Bai L, Mesgarzadeh S, Ramesh KS, et al. Cell 2019 Nov | PMID: 31730854 |
| Wu JS, Yi E, Manca M, et al. Elife 2020 Jan | PMID: 31975688 |
| Nguyen R, Venkatesan S, Binko M, et al. J Neurosci 2020 Jan | PMID: 32005764 |
| Touahri Y, Dixit R, Kofoed RH, et al. Theranostics 2020 | PMID: 32194850 |
| Yoon S, Parnell E, Kasherman M, et al. Neuron 2020 Feb | PMID: 31813652 |
| Cherqui S - US Patent App. 16/820,368, 2020 | |
| Liu CY, Tsai CJ, Yasugaki S, et al. Neurosci Res 2020 Apr | PMID: 32283105 |
| Hastings RL, Massopust RT, Haddix SG. Skelet Muscle 2020 May | PMID: 32381068 |
| Sun W, PhD Thesis, Otto von Guericke University Magdeburg, Germany 2020 | |
| Neubarth NL, Emanuel AJ, Liu Y, et al. Science 2020 Jun | PMID: 32554568 |
| Mikedis MM, Fan Y, Nicholls PK, et al. Elife 2020 Jul 20 | PMID: 32686646 |
| Ceto S, Sekiguchi KJ, Takashima Y, et al. Cell Stem Cell 2020 Jul | PMID: 32758426 |
| MacDonald AJ, Holmes FE, Beall C, et al. Glia 2020 Jun | PMID: 31880353 |
| Takahashi TM, Sunagawa GA, Soya S, et al. Nature 2020 Jun | PMID: 32528181 |
| Cheung P, Xiol J, Dill MT, et al. Cell Stem Cell 2020 Jul | PMID: 32730753 |
| Niu X, Liu L, Wang T, et al. J Neurosci 2020 Jul | PMID: 32690615 |
| Lewis EM, Stein-O'Brien GL, Patino AV, et al. Neuron 2020 Nov | PMID: 33113347 |
| Yu Q, Du, M Zhang W, et al. Cell Mol Gastroenterol Hepatol 2020 Dec | PMID: 33340715 |
| Towler B, Pashler A, Haime H, et al. bioRxiv 2021 | |
| Call CL and Bergles DE. bioRxiv 2021 | |
| Kaise T and Kageyama R. Gene Expression Patterns Mar 2021 | PMID: 33675998 |
| Sanchez-Aguilera A, Wheeler DW, Jurado-Parras T, et al. PLoS Biol. 2021 May | PMID: 33956790 |
| Escrevente C, Bento-Lopes L, Ramalho JS, et al. J Cell Sci 2021 May | PMID: 34002205 |
| Pusic KM, Kraig RP, Pusic AD, et al. PLoS One 2021 Aug | PMID: 34388189 |
| Sun W, Choi I, Stoyanov S, et al. Nat Commun 2021 Oct | PMID: 34663792 |
| Wiegmann RP. PhD Thesis, Universit?tsklinikum Hamburg Eppendorf, Hamburg, Germany 2021 | |
| Ferreira JV, Soares AR, Ramalho J, et al. Sci Adv 2022 Mar | PMID: 35333565 |
| Call CL, Neely SA, Early JJ, et al. bioRxiv Feb 2022 | |
| Yoshinaga S, Honda T, Kubo KI, et al. Neurosci Res 2022 Mar | PMID: 35364133 |
| Hermanns T, Graf-Boxhorn S, Poeck B et al. Curr Biol 2022 Jul | PMID: 35914533 |
| Bassi JK, Connelly AA, Butler AG, et al. J Comp Neurol 2022 Aug | PMID: 35988033 |
| Boudjadja MB, Culotta I, Paula GCD, et al. Curr Biol 2022 Sep | PMID: 36182699 |
| Letchuman S, Tucker A, Miranda D, et al. eNeuro 2022 Oct | PMID: 36265906 |
| Takahashi TM, Hirano A, Kanda T, et al. Cell Rep Methods 2022 Nov | PMID: 36452866 |
SICGEN antibodies是一家葡萄牙生物技術(shù)公司,專門研發(fā)和生產(chǎn)用于生命科學(xué)研究的多克隆抗體。與單克隆抗體相比,多克隆抗體具有多表位、生產(chǎn)速度快、競爭力強(qiáng)等優(yōu)點(diǎn)。作為一抗或二抗,它們可用于各種不同的技術(shù),如ELISA, FACS, IF, IHC, IP, WB等。公司利用J端技術(shù),以Z優(yōu)的質(zhì)量和最具競爭力的價(jià)格,致力于成為世界多克隆抗體及抗體相關(guān)產(chǎn)品和服務(wù)的提供商。
艾美捷已與SICGEN antibodies達(dá)成戰(zhàn)略合作,SICGEN antibodies授予艾美捷作為其在中國區(qū)(含港澳臺)的獨(dú)家代理,全權(quán)負(fù)責(zé)SICGEN antibodies在中國的推廣和銷售工作。作為SICGEN antibodies在中國的區(qū)域總代理,艾美捷科技有限公司將為中國客戶提供全面的SICGEN antibodies產(chǎn)品,歡迎大家隨時(shí)聯(lián)系我們。
微信掃碼在線客服